Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Andrew J., Barrans, Sharon, Stanton, Louise, Caddy, Josh, Wilding, Sam, Saunders, Geoff, Mamot, Christoph, Novak, Urban, McMillan, Andrew, Fields, Paul, Collins, Graham P., Stephens, Richard, Cucco, Francesco, Sha, Chulin, van Hoppe, Moniek, Tooze, Reuben, Davies, John R., Griffiths, Gareth, Schuh, Anna, Burton, Catherine, Westhead, David R., Du, Ming-Qing, Johnson, Peter W.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
CLINICAL TRIAL UPDATES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414744/
https://www.ncbi.nlm.nih.gov/pubmed/36972491
http://dx.doi.org/10.1200/JCO.23.00033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414744/
https://www.ncbi.nlm.nih.gov/pubmed/36972491
http://dx.doi.org/10.1200/JCO.23.00033

Ejemplares similares